2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1290

Pro-Inflammatory and Anti-Inflammatory Roles Of Interferon Regulatory Factor 5 In The Development Of Collagen-Induced Arthritis
Abstract Number: 1636

Pro-Inflammatory HDL and Subclinical Atherosclerosis Are Associated With Altered Expression Of Epigenetic and Oxidative Stress-Related Gene Transcripts In SLE
Abstract Number: 1867

Profiling Cytokine Production Of B Cells From SLE Patients Upon TLR9 Stimulation
Abstract Number: 1342

Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria
Abstract Number: 1309

Prognosis Of Seronegative Patients In a Large Prospective Cohort Of Patients With Early Inflammatory Arthritis
Abstract Number: 2627

Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet’s Disease
Abstract Number: 583

Prognostic Significance Of Visit-To-Visit Variability, Maximum Systolic Blood Pressure, and Episodic Hypertension In Sytemic Lupus Erythematosus
Abstract Number: 2879

Prognostic Value Of Minor Salivary Gland Assessments In Primary Sjögren’s Syndrome
Abstract Number: 1871

Progranulin Directly Binds To The CRD 2 and CRD3 Of TNFR Extracellular Domains
Abstract Number: 1625

Prolactin-Induced Interferon Regulatory Factor 1 Activation and Histone H4 Hyperacetylation In Monomac-6 Cells Correlating With Changes Seen In Monocytes From Systemic Lupus Erythematosus Patients
Abstract Number: 369

Prolongation Of QT Interval In Patients With Rheumatoid Arthritis and Its Impact On Mortality: Results From a Population-Based Study
Abstract Number: 992

Promise Of Behavioral Economics: Delay Discounting and Physical Activity In Patients With Musculoskeletal Diseases
Abstract Number: 980

Promoting Critical Appraisal Self-Efficacy and Peer Connectivity With An Epidemiology Curriculum For Rheumatology Trainees
Abstract Number: 2693

Proof Of Concept: Enthesitis and New Bone Formation In Spondyloarthritis Are Driven By Mechanical Strain and Stromal Cells
Abstract Number: 2002

Prophylactic Duration and Serum Uric Acid Level Are Associated With Gout Flare During Urate Lowering Treatment

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].